oxybutynin has been researched along with Dyskinesia, Drug-Induced in 1 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Primary outcomes included adverse events (AEs) and extent of rotigotine exposure." | 2.78 | The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease. ( Boroojerdi, B; Giladi, N; Surmann, E, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giladi, N | 1 |
| Boroojerdi, B | 1 |
| Surmann, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Extension to the Double-Blind SP513 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease[NCT00599196] | Phase 3 | 381 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment. (NCT00599196)
Timeframe: six years
| Intervention | Subjects (Number) |
|---|---|
| Rotigotine | 93 |
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment. (NCT00599196)
Timeframe: six years
| Intervention | Subjects (Number) |
|---|---|
| Rotigotine | 369 |
The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness. (NCT00599196)
Timeframe: Visit 10 (end of year 1), Visit 14 (end of year 2), Visit 18 (end of year 3), Visit 22 (end of year 4), Visit 26 (end of year 5), Visit 30 (end of year 6), End of Treatment (last study visit or early withdrawal visit)
| Intervention | Score on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Visit 10 (end of year 1) (n=375) | Visit 14 (end of year 2) (n=375) | Visit 18 (end of year 3) (n=375) | Visit 22 (end of year 4) (n=375) | Visit 26 (end of year 5) (n=375) | Visit 30 (end of year 6) (n=375) | End of Treatment (n=377) | |
| Rotigotine | 5.8 | 6.2 | 6.7 | 6.7 | 6.7 | 6.8 | 6.8 |
1 trial available for oxybutynin and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Topics: Adolescent; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combin | 2013 |